A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate.
Imatinib mesylate (IM) is used to treat a wide range of diseases, including Philadelphia chromosome-positive chronic myeloid leukemia (CML), on account of its high tolerability and low incidence of minor adverse events. Hemorrhage is thought to be a rare complication of IM. Recently, IM has been associated with reduced α2-plasmin inhibitor and platelet dysfunction. We report here the case of a 33-year-old female patient with CML who experienced subdural hematoma after an incremental increase in IM dosage due to a loss of complete molecular response. This case indicates that physicians should be alert to this atypical cause of headache in patients taking high-dose IM.
Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Min Sik
MS
Kim
Dong Hyun
DH
Lee
Yu Rim
YR
Lee
Dong Kyun
DK
Kim
Suk Hyang
SH
Bae
Jin Yeon
JY
Hwang
Kyung A
KA
Kwon
Suee
S
Lee
Jin Yeong
JY
Han
Ki Uk
KU
Kim
Sung-Hyun
SH
Kim